AUTHORS
Iris Nicola Lommerse, Constantijn Halkes, MD2, Jennifer Tjon3, Simona Iacobelli4, Joe Tuffnell5, Brian Piepenbroek6, Camilla Frieri7, Flore Sicre-de-Fontbrune, MD8, Roochi Trikha, PhD,FRPATH,MBChB,MRCP9, Morag Griffin, FRCPath, MBChB, MRCP10, Christian Recher11, Fiorenza Barraco12, Beatrice Drexler, MD13, Edouard Forcade, MD, PhD14, Carlos Vallejo, MD15, Carlo Dufour I, MD16, Austin G. Kulasekararaj, MD, MBBS, FRCPath, MRCP17, Regis Peffault De Latour, MD, PhD18, Antonio M. Risitano Jr, MD, PhD19
AFFILIATIONS
1 Leiden University Medical Center, Leiden, Netherlands
2 Leiden University Medical Center, Leiden, Netherlands
3 Leiden University Medical Center, Leiden, Netherlands
4 EBMT, Leiden, Netherlands
5 EBMT, Leiden, Netherlands
6 EBMT, Leiden, Netherlands
7 AORN S. Giuseppe Moscati, Avellino, Italy, EBMT, Leiden, Netherlands, Federico II University, Naples, Italy, Saint-Louis Hospital and Université de Paris, Paris, France
8 Saint-Louis Hospital and Université de Paris, Paris, France
9 King's College Hospital NHS Foundation Trust, London, United Kingdom
10 St James’s University Hospital, Leeds, United Kingdom
11 Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France
12 Centre Hospitalier Universitaire Lyon Sud, Lyon, France
13 University Hospital Basel, Basel, Switzerland
14 Hôpital Haut-Leveque, Pessac, France
15 University Hospital of Salamanca, Salamanca, Spain
16 IRCCS Istituto G Gaslini, Genova, Italy
17 EBMT, Leiden, Netherlands, King's College Hospital NHS Foundation Trust, London, United Kingdom
18 EBMT, Leiden, Netherlands, Saint-Louis Hospital and Université de Paris, Paris, France
19 AORN S. Giuseppe Moscati, Avellino, Italy, EBMT, Leiden, Netherlands, Federico II University, Naples, Italy
ABSTRACT
Introduction
Antithymocyte globulin (ATG) combined with ciclosporin (CsA) is a long-established and effective treatment for aplastic anemia (AA) and remains the preferred first-line immunosuppressive therapy (IST). The EBMT RACE study (1), an international multicenter randomized clinical trial, compared response rates and survival after standard IST (ATG and CsA) with and without the addition of eltrombopag. QoL, assessed using the EORTC-QLQ-c30, did not differ significantly between the two treatment arms. However, a recent study indicated that AA patients after IST with partial recovery of blood values (PR) experienced lower QoL than patients with complete recovery (CR) (2), suggesting that QoL relates to depth of treatment response. This post-hoc analysis evaluated the effect of treatment response on QoL of AA patients treated within the RACE trial.
Methods
The EORTC QLQ-C30 assesses QoL on 0–100 scales. Higher scores indicate better QoL except for fatigue, where higher scores indicate greater symptom burden. Participants of the RACE trial completed the questionnaire at baseline, 6, 12 and 24 months. For this post-hoc analysis we studied QoL within the first year after starting treatment. Treatment response was defined as no response (NR), complete response (CR: recovery of hemoglobin levels above 10g/dL, a neutrophil count greater than 1000/mm2 and platelets above 100,000/mm2), or partial response (PR, transfusion independence, but no CR), regardless of whether this was achieved after first-line or subsequent treatment. Patients were censored at clonal evolution or allogeneic stem cell transplantation. A linear mixed model with treatment response as a time-dependent variable and age, time and baseline QoL as covariates, was used to compare estimated mean QoL scores across the different treatment response groups. Unpaired t-tests were used for comparisons at 6 and 12 months and within-patient changes over time were evaluated with paired t-tests.
Results
At baseline 192 patients were included in the analysis, of whom 166 completed the questionnaire. Three (cognitive functioning, pain and financial difficulties) of the 9 assessed QoL subscales showed a ceiling effect at baseline and were therefore not included in further analyses. Included in the analysis were physical functioning, role functioning, emotional functioning, social functioning, global health status and fatigue. At 6 months, with 147 completed questionnaires, 69 patients were NR, 55 were PR and 53 CR. At 12 months (129 questionnaires) 23 patients were NR, 59 PR and 71 CR. The linear mixed model showed that NR patients scored significantly worse than patients with response (PR or CR) on all QoL domains (estimated mean differences > 8 points; p<0.01), except for emotional functioning (estimated mean difference 5 points; p=0.12). CR patients tended to score better than PR patients, although these differences did not reach statistical significance. The most pronounced differences were observed in social functioning: estimated means were 7 points higher in CR patients than in PR patients (p=0.09), and 23 points higher than in NR patients (p<0.001). Zooming in on the differences between PR and CR patients, unpaired t-tests showed that at 6 months, CR patients scored 6 points higher on global health (p=0.11) and 8 points lower on fatigue (p=0.07) than PR patients. By 12 months the differences on these domains were smaller (both 3 points), while differences in physical (6 points; p=0.07) and social functioning (8 points; p=0.08) became more pronounced. Paired t-tests further showed that patients who improved from PR at 6 months to CR at 12 months (n=21) also improved in QoL over this period, although only the change in social functioning reached statistical significance (12 points, p=0.02). Patients who remained in PR between 6 and 12 months (n=30) showed no clear change in QoL.
Conclusion
Patients not responding to IST scored significantly worse on all evaluated QoL domains than responders within the first year after IST. Moreover, a discernible trend emerged in which patients achieving CR experienced better QoL than those in PR. At 6 months, CR patients experienced most notably less fatigue, whereas at 12 months, differences were more pronounced for social and physical functioning scales. Therefore, aiming for the best possible response after IST seems to pay off twice: in blood counts, and in patients’ quality of life.
DISCLOSURES
Iris Nicola Lommerse: No relevant conflicts of interest to declare.